Last updated: August 29, 2026
Lysteda, the branded 650 mg oral tranexamic acid tablet, has moved from protected specialty therapy to a mature, generic-exposed product. Its commercial value depends on brand retention, physician familiarity, supply reliability, and reimbursement rather than molecular novelty. Tranexamic acid has been used for decades, and generic tablets now compete directly with Lysteda in the U.S. market. Public sources do not disclose standalone Lysteda revenue, so the financial trajectory must be assessed through regulatory timing, competitive entry, pricing pressure, and the size of the heavy menstrual bleeding segment.
What is Lysteda and how is it used?
Lysteda is an oral formulation of tranexamic acid indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. The FDA-approved regimen is 1,300 mg orally three times daily for a maximum of five days during each menstrual cycle, equal to four 650 mg tablets per day and a maximum of 20 tablets per treatment cycle.[1]
| Product |
Active ingredient |
Strength |
Dosage form |
FDA indication |
| Lysteda |
Tranexamic acid |
650 mg |
Oral tablet |
Cyclic heavy menstrual bleeding |
| Generic tranexamic acid |
Tranexamic acid |
650 mg |
Oral tablet |
Same or substantially equivalent indication, subject to approved labeling |
Tranexamic acid is an antifibrinolytic. It reduces menstrual blood loss by inhibiting plasminogen activation and plasmin activity. Lysteda competes against hormonal contraceptives, levonorgestrel-releasing intrauterine systems, nonsteroidal anti-inflammatory drugs, endometrial ablation, and surgical treatment.
The product is commercially distinct from intravenous tranexamic acid products used in trauma, surgery, postpartum hemorrhage, and other hospital settings. Lysteda’s value is tied to outpatient gynecology and women’s health rather than hospital-administered tranexamic acid.
When did Lysteda receive FDA approval and exclusivity?
The FDA approved Lysteda under NDA 022430 in November 2009.[2] The approval covered a new oral tablet presentation and a specific indication for cyclic heavy menstrual bleeding.
Because tranexamic acid was an established active ingredient, Lysteda did not receive the same market position as a new molecular entity based on a newly discovered active pharmaceutical ingredient. Its regulatory protection came from the product-specific NDA, listed patents, and any applicable formulation or indication exclusivity.
| Milestone |
Timing |
Commercial effect |
| FDA approval of Lysteda NDA 022430 |
November 2009 |
Established branded U.S. oral product |
| Initial regulatory exclusivity period |
Ended during the early 2010s |
Removed the principal FDA approval barrier for competing applications |
| Generic approval and commercialization |
After patent and regulatory barriers were addressed |
Created direct price competition |
| Current market position |
Mature, generic-exposed |
Brand value depends on residual prescribing and contracting |
The exact date of any remaining patent protection must be determined from the current FDA Orange Book and relevant patent records. FDA’s Orange Book is the controlling source for patents formally listed against an approved drug application.[3]
What patents protect Lysteda?
Lysteda’s patent protection was directed primarily to the oral formulation, dosing approach, and use of tranexamic acid for heavy menstrual bleeding rather than to the underlying molecule itself.
Tranexamic acid is an old active pharmaceutical ingredient. Its basic composition-of-matter protection is not commercially relevant. The defensible intellectual-property categories were:
- Tablet formulation and physical characteristics.
- Oral dosing for cyclic heavy menstrual bleeding.
- Treatment methods using defined doses over a limited number of menstrual days.
- Manufacturing or formulation parameters, where separately claimed.
The distinction matters because formulation and method-of-use patents are generally narrower than composition-of-matter patents. Generic applicants can challenge them through Paragraph IV certifications, carve out protected indications, or rely on approved labeling that does not infringe a particular method claim.
What is the Orange Book status of Lysteda?
Lysteda’s Orange Book status should be reviewed against NDA 022430 for current patent listings, delisting activity, and any associated exclusivity codes. Orange Book listings do not establish that every listed patent will survive litigation or be infringed by a specific generic product. They identify patents submitted by the NDA holder and accepted for listing by FDA under applicable rules.[3]
The most important commercial conclusion is that generic tranexamic acid tablets have entered the U.S. market. That indicates that any Lysteda patent estate no longer prevents all direct competition. Remaining patents, if any, may still affect particular formulations or labeling strategies, but they do not preserve broad exclusivity for the product.
When did Lysteda lose exclusivity?
Lysteda lost its practical exclusivity when generic tranexamic acid 650 mg tablets became available. The relevant commercial event is generic launch, not simply the expiration of the last listed patent.
The product’s protection likely eroded in stages:
- FDA regulatory exclusivity ended after the initial post-approval period.
- Patent barriers were challenged, expired, narrowed, or otherwise bypassed.
- Generic manufacturers obtained FDA approval.
- Pharmacy substitution and formulary pressure reduced the brand’s ability to sustain premium pricing.
For a product based on an established molecule, generic entry typically causes a sharper decline in net price than in patient demand. Patients may continue using tranexamic acid, but the prescription can shift from Lysteda to an approved generic.
Which companies are challenging or competing with Lysteda?
The principal competitors are manufacturers of generic tranexamic acid tablets. FDA approval records identify the individual ANDA sponsors and approval dates. The competitive set can change as additional manufacturers enter or discontinue supply.
The relevant competitive categories are:
| Competitor category |
Competitive impact |
| Generic tranexamic acid 650 mg tablets |
Direct substitution and price erosion |
| Other oral tranexamic acid strengths |
Potential dose flexibility, though not always therapeutically interchangeable |
| Hormonal therapies |
Compete for first-line treatment of heavy menstrual bleeding |
| Levonorgestrel intrauterine systems |
Compete through longer-term bleeding reduction |
| NSAIDs |
Compete in patients with pain and moderate bleeding |
| Endometrial ablation and surgery |
Compete in refractory or completed-childbearing populations |
Generic tranexamic acid is the most important competitive threat because it preserves the same active ingredient, route, and core treatment concept. Other therapies compete for the patient rather than directly replacing the tablet.
What generic entry risks exist for Lysteda?
Generic entry has already converted Lysteda from a protected branded product into a mature brand. The principal risks are:
Price erosion
Wholesale acquisition cost and net realized price generally decline after generic entry. Pharmacy benefit managers and wholesalers can use generic availability to reduce reimbursement for the branded product.
Volume substitution
The same prescriber may continue prescribing tranexamic acid while the pharmacy dispenses a generic product. This preserves category demand but reduces Lysteda prescriptions.
Formulary exclusion
Health plans may prefer generic tranexamic acid and impose higher copayments, prior authorization, or nonpreferred status on Lysteda.
Labeling competition
A generic applicant may use a Paragraph IV challenge against listed patents or a Section viii statement to omit a patented method of use. For Lysteda, the narrow indication and established active ingredient make labeling strategy important.
Supply competition
Tranexamic acid is manufactured by multiple international suppliers. Generic availability can be affected by API sourcing, manufacturing observations, and shortages, but a single-source brand generally has less pricing power once alternative suppliers are established.
What is Lysteda’s financial trajectory?
Lysteda’s financial trajectory is best characterized as a decline from launch-stage branded growth to mature-product cash generation.
Launch and adoption phase: 2009 to the mid-2010s
Lysteda entered a market in which heavy menstrual bleeding was commonly treated with hormonal methods, intrauterine systems, NSAIDs, and procedures. Its commercial differentiation was a nonhormonal oral option used only during menstruation.
The product could command a branded price because it offered:
- A defined FDA indication.
- A short, intermittent treatment course.
- A nonhormonal mechanism.
- Physician familiarity with tranexamic acid from other clinical settings.
Growth was constrained by the fact that tranexamic acid was already known and available in other dosage forms, including products used outside the Lysteda indication.
Generic transition phase
Once generic 650 mg tablets became available, Lysteda faced direct substitution. The financial effects were likely:
- Lower net price.
- Reduced branded prescription volume.
- Lower pharmacy benefit manager reimbursement.
- Increased promotional difficulty.
- Greater reliance on brand loyalty and supply consistency.
No public filing provides a separately reported Lysteda revenue series. Ferring is privately held, and publicly available company disclosures do not provide a recurring product-level revenue breakdown for Lysteda. As a result, precise annual sales, gross margin, and contribution profit cannot be established from public financial statements.
Mature-product phase
Lysteda can continue generating revenue after generic entry if it retains:
- Prescriber recognition.
- Patient preference for the branded product.
- Coverage in selected commercial plans.
- Reliable pharmacy distribution.
- A price premium that is acceptable to patients and payers.
The likely economic profile is a smaller but more stable revenue stream. The product requires limited treatment exposure because patients typically use it for only several days per cycle. That limits annual tablet consumption per patient and places greater importance on patient acquisition and refill persistence.
How large is the market for Lysteda?
The addressable market is women with clinically significant heavy menstrual bleeding who need medical treatment and are suitable for antifibrinolytic therapy. The broader condition affects a substantial share of menstruating patients, but the treated market is smaller because many patients use hormonal therapy, do not seek care, or proceed to procedural treatment.
Lysteda’s commercial market is narrowed by several factors:
- Contraindications or concerns involving thrombosis risk.
- Need to evaluate abnormal uterine bleeding.
- Renal dosing considerations.
- Limited use outside the menstrual bleeding window.
- Competition from long-acting hormonal options.
- Generic availability.
The product has a stronger position among patients seeking nonhormonal therapy, patients who want episodic rather than continuous treatment, and patients who cannot or do not want to use estrogen-containing contraceptives.
What FDA safety and regulatory issues affect Lysteda?
The FDA labeling identifies thromboembolic risk and contraindications involving active thromboembolic disease, a history of thrombosis, or an intrinsic risk of thrombosis.[1] Concomitant use with combined hormonal contraceptives is a significant labeling issue because of the potential for increased thrombotic risk.
Other regulatory and prescribing considerations include:
- Dose adjustment in renal impairment.
- Ocular or visual symptoms requiring evaluation.
- Need to exclude undiagnosed causes of abnormal uterine bleeding.
- Avoidance in patients with certain color-vision disturbances or relevant ophthalmic risks, depending on the clinical context.
These restrictions limit the addressable patient pool but also support the product’s positioning as a defined, physician-managed therapy rather than an unrestricted over-the-counter product.
What licensing deals affect Lysteda?
No major publicly disclosed licensing transaction currently establishes a separate, transparent financial stream for Lysteda. The brand has been associated with Ferring Pharmaceuticals, which markets pharmaceutical products in women’s health and other specialty areas.
Because Ferring is privately held and does not publish a complete product-level income statement, external analysts cannot reliably calculate Lysteda’s revenue, royalty burden, transfer pricing, or EBITDA contribution from public information.
How strong is the Lysteda patent estate?
The estate is commercially weaker than the patent estate of a new chemical entity because:
- Tranexamic acid is a long-established molecule.
- Generic manufacturers can rely on the known active ingredient.
- Formulation claims are narrower than composition claims.
- Method-of-use claims can be challenged or carved out.
- Direct generic products are already available.
The remaining value of any unexpired patents would depend on claim scope, enforceability, listing status, and whether generic labels practice the claimed method. Patent protection may still create litigation leverage, but it does not restore broad market exclusivity after generic launch.
What generic launch scenarios exist for Lysteda?
The main scenarios are:
| Scenario |
Expected effect |
| Broad generic substitution |
Rapid brand price and volume decline |
| Limited generic supply |
Lysteda retains temporary share and pricing stability |
| Additional generic entrants |
Greater price erosion and lower brand retention |
| Brand contracting strategy |
Slower decline but lower net price |
| Generic manufacturing disruption |
Short-term brand recovery or supply gains |
| Increased use of nonhormonal therapy |
Category growth that may benefit both brand and generic products |
The most probable long-term scenario is continued generic dominance with residual branded demand. Category growth would not necessarily translate into equivalent Lysteda growth because new patients are likely to receive the lowest-cost covered product.
Key Takeaways
- Lysteda is the branded 650 mg oral tranexamic acid product approved for cyclic heavy menstrual bleeding.
- FDA approved Lysteda NDA 022430 in November 2009.
- The active ingredient is old, so the commercial patent estate was based mainly on formulation and method-of-use claims.
- Generic tranexamic acid tablets have entered the U.S. market, ending practical product exclusivity.
- Brand revenue is likely in a mature-product decline phase, with no publicly reported standalone sales figure.
- The strongest remaining commercial defenses are prescriber familiarity, patient preference, distribution reliability, and payer access.
- Hormonal therapies, levonorgestrel intrauterine systems, NSAIDs, ablation, and surgery compete with Lysteda at the treatment-category level.
- FDA safety restrictions involving thrombosis, renal impairment, and drug interactions limit patient eligibility.
- Lysteda’s patent estate is materially weaker than the estate of a new molecular entity because generic manufacturers can use the established tranexamic acid molecule.
- Future value is more likely to come from residual brand cash flow and category demand than from renewed exclusivity.
FAQs
Is Lysteda the same as tranexamic acid?
Lysteda is a branded oral tranexamic acid tablet. Generic tranexamic acid tablets contain the same active ingredient and may be therapeutically substitutable when approved for the relevant use.
Can Lysteda be purchased over the counter?
Lysteda is an FDA-approved prescription product. Tranexamic acid products sold in other countries or in different dosage forms may have different regulatory classifications.
Does Lysteda have biosimilar competition?
No. Lysteda is a small-molecule drug, not a biologic. Its competitive threat comes from generic drug applicants rather than biosimilar developers.
Does Lysteda compete with birth-control products?
Yes. Hormonal contraceptives, including combined oral contraceptives and levonorgestrel intrauterine systems, are important alternatives for heavy menstrual bleeding. Lysteda is positioned as a nonhormonal, intermittent treatment.
What would increase Lysteda’s commercial value?
Improved payer coverage, sustained generic supply disruptions, stronger physician adoption of nonhormonal treatment, and expanded use in appropriate patients could support sales. A new patent or FDA-approved indication would have greater strategic value than ordinary brand promotion, but no such expansion should be assumed without a specific regulatory filing.
References
- U.S. Food and Drug Administration. (2021). Lysteda (tranexamic acid) tablets prescribing information.
- U.S. Food and Drug Administration. (2009). FDA approves Lysteda for heavy menstrual bleeding.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
